| Cell Reports Medicine | 卷:2 |
| Molecular predictors of response to pembrolizumab in thymic carcinoma | |
| Archana Ramesh1  Krithika Bhuvaneshwar2  Yuriy Gusev2  Giuseppe Giaccone3  Yongfeng He3  | |
| [1] Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, 20057, USA; | |
| [2] Innovation Center of Biomedical Informatics (ICBI), Georgetown University Medical Center, Washington, DC, 20007, USA; | |
| [3] Meyer Cancer Center, Weill Cornel Medicine, New York, NY 10065, USA; | |
| 关键词: thymic carcinoma; immune checkpoint inhibitors; whole exome sequencing; whole-transcriptome sequencing; predictors of response; | |
| DOI : | |
| 来源: DOAJ | |
【 摘 要 】
Summary: Thymic carcinoma is rare and has a poorer prognosis than thymomas. The treatment options are limited after failure of platinum-based chemotherapy. We previously performed a single-center phase II study of pembrolizumab in patients with advanced thymic carcinoma, showing a 22.5% response rate. Here, we characterize the genomic and transcriptomic profile of thymic carcinoma samples from 10 patients (5 non-responders versus 5 responders) in this cohort, with the main aim of identifying potential predictors of response to immunotherapy. We find that expression of PDL1 and alterations in genes or pathways that correlated with PD-L1 expression (CYLD and BAP1) could be potential predictors for response or resistance to immunotherapy in patients with advanced thymic carcinoma. Our study provides insights into potential predictive markers/pathways to select patients with thymic carcinoma for anti-PD-1 immunotherapy.
【 授权许可】
Unknown